ALIM - アリメラ・サイエンシ―ズ （Alimera Sciences Inc.） アリメラ・サイエンシ―ズALIMのチャート
ALIMの企業情報
| symbol | ALIM |
|---|---|
| 会社名 | Alimera Sciences Inc. （アリメラ・サイエンシ―ズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アリメラ・サイエンシーズ(Alimera Sciences Inc.)は処方眼科医薬品の研究・開発・商業化を専門に扱うバイオ医薬品企業。同社は眼底や網膜に影響を与える疾患を中心に取り扱う。同社の製品候補「ILUVIEN」は非外科的治療手順であり、25ゲージ針付きのデバイスを採用し、傷のセルフシールを可能にする。また、「ILUVIEN」はドライ型加齢黄斑変性症（AMD）、ウェット型AMD及び網膜静脈閉塞症（RVO）を治療するために３つの第２相臨床試験で研究されている。「ILUVIEN」は硝子体内インプラントであり、非独占の副腎皮質ステロイドであるフルオシノロンアセトニド（FAc）の持続的なサブマイクログラムレベルを提供することにより、糖尿病性黄斑浮腫（DME）に関連する視力障害の治療で最大36ヶ月の治療効果を提供する。 アリメラ・サイエンシ―ズは米国のバイオ医薬品メ―カ―。眼科薬の研究、開発、商業化に従事。主に、眼球の裏側や網膜に影響を及ぼす疾患に焦点を当てている。慢性糖尿病性黄斑浮腫に関連した視力障害治療薬「イルビエン」は、英国、オ―ストリア、ポルトガル、フランス、ドイツ、スペインで販売承認を受けている。本社はジョ―ジア州。 |
| 本社所在地 | 6120 Windward Parkway Suite 290 Alpharetta GA 30005 USA |
| 代表者氏名 | Richard S. Eiswirth リチャードエスワース |
| 代表者役職名 | President Chief Financial Officer |
| 電話番号 | +1 678-990-5740 |
| 設立年月日 | 37773 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2010年 |
| 従業員数 | 126人 |
| url | www.alimerasciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/alim |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.46000 |
| 終値（lastsale） | 0.931 |
| 時価総額（marketcap） | 65205760.641 |
| 時価総額 | 時価総額（百万ドル） 66.07424 |
| 売上高 | 売上高（百万ドル） 39.64500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 156.19224 |
| 当期純利益 | 当期純利益（百万ドル） -24.19300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Alimera Sciences Inc revenues increased 22% to $20.7M. Net loss increased 23% to $11.7M. Revenues reflect United States segment increase of 20% to $15M International segment increase of 28% to $5.7M. Higher net loss reflects United States segment loss increase of 21% to $2.7M International segment loss increase of 27% to $1.2M. |
ALIMのテクニカル分析
ALIMのニュース
Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference 2021/01/05 13:00:00 GlobeNewswire
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of…
Alimera Sciences Announces Third Quarter 2020 Financial Results 2020/10/28 20:05:00 GlobeNewswire
Rebound Continues from COVID Challenges
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update 2020/10/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update 2020/07/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates 2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Announces Third Quarter 2020 Financial Results 2020/10/28 20:05:00 GlobeNewswire
Rebound Continues from COVID Challenges
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update 2020/10/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update 2020/07/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates 2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Refinances Debt Facility With Solar Capital 2020/01/06 14:08:25 Investing News Network
Alimera announced it has entered into a new US$45 million term loan agreement with investment affiliates managed by Solar Capital Partners. The post Alimera Sciences Refinances Debt Facility With Solar Capital appeared first on Investing News Network .
Alimera Sciences Announces Third Quarter 2020 Financial Results 2020/10/28 20:05:00 GlobeNewswire
Rebound Continues from COVID Challenges
Alimera Sciences to Report Third Quarter 2020 Financial Results on Wednesday, October 28, 2020 and Provide Corporate Update 2020/10/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, October 29, 2020 at 9:00am Eastern Time
Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update 2020/07/22 12:00:00 GlobeNewswire
Conference Call to be held Thursday, July 30, 2020 at 9:00 AM Eastern Time
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates 2020/04/29 22:25:08 Zacks Investment Research
Alimera Sciences (ALIM) delivered earnings and revenue surprises of 44.19% and 3.53%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Refinances Debt Facility With Solar Capital 2020/01/06 14:08:25 Investing News Network
Alimera announced it has entered into a new US$45 million term loan agreement with investment affiliates managed by Solar Capital Partners. The post Alimera Sciences Refinances Debt Facility With Solar Capital appeared first on Investing News Network .